Research presented at the ASCO Annual Meeting 2025 highlighted new potential standards of care and other advances in breast cancer.

Dr Heather McArthur describes how ASCO 2025 showcased new standards of care in triple-negative and HER2-positive settings.

The drug Trodelvy (drug name sacituzumab govitecan-hziy) is showing promise for first-line metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitors (treatments that ...

Survival outcomes with the sacituzumab govitecan combination outweighed outcomes with chemotherapy combination therapy. Researchers reported no new safety concerns with the sacituzumab govitecan ...

In patients with an aggressive form of breast cancer, treatment with the antibody-drug conjugate sacituzumab govitecan plus pembrolizumab resulted in durable responses with improved progression free ...

Interim results reveal promising efficacy and safety of sacituzumab govitecan and pembrolizumab for muscle-invasive bladder ...

Sacituzumab govitecan-hziy significantly improved progression free survival over standard chemotherapy in untreated mTNBC patients ineligible for immunotherapy. Topline data were announced from a ...

Sacituzumab govitecan targets Trop-2 and delivers potent chemo directly to TNBC cells. PARP inhibitors are effective in TNBC patients with BRCA mutations. Immune checkpoint inhibitors benefit ...

Study participants were randomly assigned 1:1 to receive either sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, plus pembrolizumab, a PD-1-blocking antibody, or chemotherapy ...

“We believe ADCs are an important modality in the treatment of cancer and are rapidly advancing the clinical development of sacituzumab tirumotecan, with the goal of meaningfully improving upon ...